Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Tocagen's Having a Rough Day

By Cory Renauer – May 22, 2019 at 1:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An interim look at the company's experimental brain cancer treatment didn't reveal the result investors wanted.

What happened

Shares of Tocagen (TOCA), a clinical-stage biopharmaceutical company, are tumbling after the company delivered a clinical-trial update that was less than terrific. Disappointed investors pushed the stock 33.3% lower as of 12:58 p.m EDT on Wednesday.

So what

Tocagen's lead candidate, Toca 511, is a retrovirus that surgeons inject directly into the cavity left when they remove a brain tumor. The complicated therapy is in a pivotal study with patients who have recurrent brain cancer, and independent data monitors recently performed an interim analysis. The 403-patient trial was allowed to continue without modification, which wasn't exactly what investors wanted to hear.

Person looking at a downward-sloping arrow crashing through the floor

Image source: Getty Images.

Investors should be breathing a sigh of relief because the data monitors didn't raise the futility flag. Instead, they're disappointed that any benefit observed wasn't strong enough to end the trial early and allow the placebo group to start active treatment.

Now what

Compared to most experimental gene therapies, Tocagen's combination treatment looks like a Rube Goldberg machine. After it's injected into tumor cavities, Toca 511 should selectively infect tumor cells and deliver a gene for the enzyme cytosine deaminase (CD).

Toca FC is an extended-release version of an old hospital-grade antifungal medication that should be converted by CD inside tumor cells to an anti-cancer drug called 5-FU. Then 5-FU is supposed to selectively harm cancer cells loaded with CD, and facilitate a tumor-chomping immune response.

Median overall survival among 23 patients treated with the combo in phase 1 was an encouraging 14.4 months, compared to a historical average of 8.5 months for similar patients. While the single-arm trial data looks convincing, placebo groups have a nasty tendency to perform much better than expected. Trying to catch this falling knife is probably a bad idea.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tocagen Inc Stock Quote
Tocagen Inc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.